Impact of glaucoma and glaucoma surgery on quality of life
DOI: 10.32364/2311-7729-2022-22-1-44-50
V.P. Erichev, A.V. Volzhanin
Scientific Research Institute of Eye Diseases, Moscow, Russian Federation
Glaucoma is a chronic, incurable disease managed by controlling intraocular pressure (IOP). Meanwhile, vision loss in glaucoma and treatments affect the quality of life (QoL). Many studies on QoL in patients with glaucoma are now available. Standardized questionnaires and established non-linear relationships between QoL in glaucoma and clinically assessed quantitative parameters (e.g., visual acuity, visual fields, etc.) are significant achievements. Although treatments (pharmacotherapy or surgical interventions) generally reduce IOP, their adverse reactions affect QoL and treatment adherence. Surgical interventions provide the most potent IOP-lowering effect. However, surgery most affects QoL due to local symptoms and psychological factors (particularly at the early stages of glaucoma). Given the emergence of minimally invasive procedures, the importance of studying de facto QoL after glaucoma surgery is resurrected.
Keywords: quality of life, glaucoma, trabeculectomy, minimally invasive glaucoma surgery, neuroprotective therapy.
For citation: Erichev V.P., Volzhanin A.V. Impact of glaucoma and glaucoma surgery on quality of life. Russian Journal of Clinical Ophthalmology. 2022;22(1):44–50 (in Russ.). DOI: 10.32364/2311-7729-2022-22-1-44-50.
About the authors:
Valeriy P. Erichev — Dr. Sc. (Med.), Professor, Chief of Scientific Direction; ORCID iD 0000-0001-6842-7164.
Andrey V. Volzhanin — C. Sc. (Med.), junior researcher; ORCID iD 0000-0002-1421-8882.
Scientific Research Institute of Eye Diseases, 11A, B, Rossolimo str., Moscow, 119021, Russian Federation.
Contact information: Andrey V. Volzhanin, e-mail: avolzhanin@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 14.12.2021.
References
1. GBD 2019 Blindness and Vision Impairment Collaborators on behalf of the Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144–e160. DOI: 10.1016/S2214-109X(20)30489-7.
2. Tham Y.C., Li X., Wong T.Y. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. DOI: 10.1016/j.ophtha.2014.05.013.
3. Neroev V.V., Zolotarev A.V., Karlova E.V. et al. Influence of treatment adherence on the progression of primary open-angle glaucoma in clinical setting. Vestn Ophtalmol. 2019;135(6):42–51 (in Russ.). DOI: 10.17116/oftalma201913506142.
4. Butt N.H., Ayub M.H., Ali M.H. Challenges in the management of glaucoma in developing countries. Taiwan J Ophthalmol. 2016;6(3):119–122. DOI: 10.1016/j.tjo.2016.01.004.
5. Agrawal P., Bradshaw S.E. Systematic Literature Review of Clinical and Economic Outcomes of Micro-Invasive Glaucoma Surgery (MIGS) in Primary Open-Angle Glaucoma. Ophthalmol Ther. 2018;7(1):49–73. DOI: 10.1007/s40123-018-0131-0.
6. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41(10):1403–1409. DOI: 10.1016/0277-9536(95)00112-k.
7. Mangione C.M., Lee P.P., Pitts J. et al. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol. 1998;116(11):1496–1504. DOI: 10.1001/archopht.116.11.1496.
8. Mangione C.M., Lee P.P., Gutierrez P.R. et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050–1058. DOI: 10.1001/archopht.119.7.1050.
9. McGwin G., Xie A., Mays A. et al. Visual field defects and the risk of motor vehicle collisions among patients with glaucoma. Invest Ophthalmol Vis Sci. 2005;46(12):4437–4441. DOI: 10.1167/iovs.05-0750.
10. Ivers R.Q., Norton R., Cumming R.G. et al. Visual impairment and risk of hip fracture. Am J Epidemiol. 2000;152(7):633–639. DOI: 10.1093/aje/152.7.633.
11. Enoch J., Jones L., Taylor D.J. et al. How do different lighting conditions affect the vision and quality of life of people with glaucoma? A systematic review. Eye (Lond). 2020;34(1):138–154. DOI: 10.1038/s41433-019-0679-5.
12. Ribeiro M.V., Hasten-Reiter Junior H.N., Ribeiro E.A. et al. Association between visual impairment and depression in the elderly: a systematic review. Arq Bras Oftalmol. 2015;78(3):197–201. DOI: 10.5935/0004-2749.20150051.
13. Mabuchi F., Yoshimura K., Kashiwagi K. et al. High prevalence of anxiety and depression in patients with primary open-angle glaucoma. J Glaucoma. 2008;17(7):552–557. DOI: 10.1097/IJG.0b013e31816299d4.
14. Jampel H.D., Frick K.D., Janz N.K. et al. Depression and mood indicators in newly diagnosed glaucoma patients. Am J Ophthalmol. 2007;144(2):238–244. DOI: 10.1016/j.ajo.2007.04.048.
15. Murphy S.L., Dubin J.A., Gill T.M. The development of fear of falling among community-living older women: predisposing factors and subsequent fall events. J Gerontol A Biol Sci Med Sci. 2003;58(10):M943–947. DOI: 10.1093/gerona/58.10.m943.
16. Janz N.K., Wren P.A., Guire K.E. et al. Fear of blindness in the Collaborative Initial Glaucoma Treatment Study: patterns and correlates over time. Ophthalmology. 2007;114(12):2213–2220. DOI: 10.1016/j.ophtha.2007.02.014.
17. Gabdrakhmanova A.F., Kurbanov S.A. Clinical and functional values of quality of life of primary open-angle glaucoma patients. National Journal glaucoma. 2015;14(4):29–35 (in Russ.).
18. Hollo G., Sandor N.G., Kothy P. et al. Influence of painless one-eye blindness on depression, anxiety and quality of life in glaucoma patients with a normal fellow eye. BMC Ophthalmol. 2021;21(1):89. DOI: 10.1186/s12886-021-01845-2.
19. Mabuchi F., Yoshimura K., Kashiwagi K. et al. Risk factors for anxiety and depression in patients with glaucoma. Br J Ophthalmol. 2012;96(6):821–825. DOI: 10.1136/bjophthalmol-2011-300910.
20. Agarkov N.M., Chukhraev A.M., Fabrikantov O.L., Yablokova N.V. Reduced quality of life in elderly patients with glaucoma. Ophthalmology in Russia. 2021;18(3):527–531 (in Russ.). DOI: 10.18008/1816-5095-2021-3-527-531.
21. Burr J.M., Kilonzo M., Vale L. et al. Developing a preference-based Glaucoma Utility Index using a discrete choice experiment. Optom Vis Sci. 2007;84(8):797–808. DOI: 10.1097/OPX.0b013e3181339f30.
22. Khachatryan N., Pistilli M., Maguire M.G. et al. A Review of Studies of the Association of Vision-Related Quality of Life with Measures of Visual Function and Structure in Patients with Glaucoma in the United States. Ophthalmic Epidemiol. 2021;28(3):265–276. DOI: 10.1080/09286586.2020.1863992.
23. Egorov E.A., Egorov A.E., Eliseeva T.O., Egorova T.E. Undesirable effects of hypotensive treatment of glaucoma. Literary review. RMJ Clinical Ophthalmology. 2011;12(3):111–113 (in Russ.).
24. Blane A. Through the Looking Glass: A Review of the Literature Investigating the Impact of Glaucoma on Crash Risk, Driving Performance, and Driver Self-Regulation in Older Drivers. J Glaucoma. 2016;25(1):113–121. DOI: 10.1097/IJG.0000000000000193.
25. Pelcic G., Ljubicic R., Barac J. et al. Glaucoma, depression and quality of life: multiple comorbidities, multiple assessments and multidisciplinary plan treatment. Psychiatr Danub. 2017;29(3):351–359. DOI: 10.24869/psyd.2017.351.
26. Mills T., Law S.K., Walt J. et al. Quality of life in glaucoma and three other chronic diseases: a systematic literature review. Drugs Aging. 2009;26(11):933–950. DOI: 10.2165/11316830-000000000-00000.
27. Nutheti R., Shamanna B.R., Nirmalan P.K. et al. Impact of impaired vision and eye disease on quality of life in Andhra Pradesh. Invest Ophthalmol Vis Sci. 2006;47(11):4742–4748. DOI: 10.1167/iovs.06-0020.
28. Kuroyedov A.V., Movsisyan A.B., Egorov E.A. et al. The profile of patients with primary open-angle glaucoma in the Russian Federation (preliminary results of a multicenter population-based study). Part 2. National Journal glaucoma. 2021;20(2):31–42 (in Russ.). DOI: 10.25700/2078-4104-2021-20-2-31-42.
29. Peters D., Heijl A., Brenner L. et al. Visual impairment and vision-related quality of life in the Early Manifest Glaucoma Trial after 20 years of follow-up. Acta Ophthalmol. 2015;93(8):745–752. DOI: 10.1111/aos.12839.
30. McKean-Cowdin R., Wang Y., Wu J. et al. Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology. 2008;115(6):941–948. DOI: 10.1016/j.ophtha.2007.08.037.
31. Van Gestel A., Webers C.A., Beckers H.J. et al. The relationship between visual field loss in glaucoma and health-related quality-of-life. Eye (Lond.). 2010;24(12):1759–1769. DOI: 10.1038/eye.2010.133.
32. Zhao C., Li J., Cun Q. et al. Impact of binocular integrated visual field defects on healthy related quality of life in glaucoma. Medicine (Baltimore). 2021;100(2):e24069. DOI: 10.1097/MD.0000000000024069.
33. Black A.A., Wood J.M., Lovie-Kitchin J.E. Inferior field loss increases rate of falls in older adults with glaucoma. Optom Vis Sci. 2011;88(11):1275–1282. DOI: 10.1097/OPX.0b013e31822f4d6a.
34. Noe G., Ferraro J., Lamoureux E. et al. Associations between glaucomatous visual field loss and participation in activities of daily living. Clin Exp Ophthalmol. 2003;31(6):482–486. DOI: 10.1046/j.1442-9071.2003.00712.x.
35. Jampel H.D. Glaucoma patients’ assessment of their visual function and quality of life. Trans Am Ophthalmol Soc. 2001;99:301–317. DOI: 10.1097/00061198-200204000-00012.
36. Purola P.K.M., Nättinen J.E., Parkkari M.M. et al. Improving health-related quality of life in glaucoma during 11 years and its association with vision loss and treatment of the disease. Acta Ophthalmol. 2022;100(1):e221–e232. DOI: 10.1111/aos.14883.
37. Kuroyedov A.V., Avdeev R.V., Alexandrov A.S. et al. Primary open-angle glaucoma: at what age and at what disease duration blindness can occur. Medical and biological problems of life. 2014;2(12):74–84 (in Russ.).
38. Heijl A., Leske M.C., Bengtsson B. et al. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–1279. DOI: 10.1001/archopht.120.10.1268.
39. Lebedev O.I., Yavorsky A.E., Kalizhnikova E.A., Kovalevsky V.V. Benzalkonium chloride as one of the causes of insufficient efficacy in glaucoma surgeries. Oftalmokhirurgiya. 2012;2:48–50 (in Russ.).
40. Maeng K.J., Lee K., Kim S. et al. Effects of Glaucoma Medication on Dry Eye Syndrome and Quality of Life in Patients with Glaucoma. Korean J Ophthalmol. 2021;35(6):467–475. DOI: 10.3341/kjo.2021.0068.
41. Egorov E.A., Brezhnev A.Yu., Egorov A.E. Neuroprotection in glaucoma: modern possibilities and prospects. RMJ Clinical ophthalmology. 2014;2:108–112 (in Russ.).
42. Erichev V.P., Petrov S.Yu., Volzhanin A.V. et al. Alpha-adrenergic receptor agonists in terms of modern views on glaucoma monitoring and treatment. RMJ Clinical Ophthalmology. 2019;19(2):87–91 (in Russ.).
43. Ryabtseva A.A. Experience in neurometabolic treatment of primary open-angle glaucoma: approaches to the stabilization of visual functions. Medvestnik. (Electronic resource.) URL: https://medvestnik.ru/content/medarticles/Opyt-neirometabolicheskogo-lecheniya-pervichnoi-otkrytougolnoi-glaukomy-podhody-k-stabilizacii-zritelnyh-funkcii.html? (access date: 10.10.2021) (in Russ.).
44. Janz N.K., Wren P.A., Lichter P.R. et al. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology. 2001;108(11):1954–1965. DOI: 10.1016/s0161-6420(01)00874-0.
45. Guedes R.A., Guedes V.M., Freitas S.M. et al. Quality of life of medically versus surgically treated glaucoma patients. J Glaucoma. 2013;22(5):369–373. DOI: 10.1097/IJG.0b013e31824ceb8b.
46. Khanna C.L., Leske D.A., Holmes J.M. Factors Associated With Health-Related Quality of Life in Medically and Surgically Treated Patients With Glaucoma. JAMA Ophthalmol. 2018;136(4):348–355. DOI: 10.1001/jamaophthalmol.2018.0012.
47. Klink T., Sauer J., Korber N.J. et al. Quality of life following glaucoma surgery: canaloplasty versus trabeculectomy. Clin Ophthalmol. 2015;9:7–16. DOI: 10.2147/OPTH.S72357.
48. Pahlitzsch M., Klamann M.K., Pahlitzsch M.L. et al. Is there a change in the quality of life comparing the micro-invasive glaucoma surgery (MIGS) and the filtration technique trabeculectomy in glaucoma patients? Graefes Arch Clin Exp Ophthalmol. 2017;255(2):351–357. DOI: 10.1007/s00417-016-3550-4.
49. Kotecha A., Feuer W.J., Barton K. et al. Quality of Life in the Tube Versus Trabeculectomy Study. Am J Ophthalmol. 2017;176:228–235. DOI: 10.1016/j.ajo.2017.01.019.
50. McLeod L.D., Coon C.D., Martin S.A. et al. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11(2):163–169. DOI: 10.1586/erp.11.12.
51. Hirooka K., Nitta E., Ukegawa K. et al. Vision-related quality of life following glaucoma filtration surgery. BMC Ophthalmol. 2017;17(1):66. DOI: 10.1186/s12886-017-0466-7.
52. Okamoto F., Okamoto Y., Fukuda S. et al. Vision-related quality of life and visual function after vitrectomy for various vitreoretinal disorders. Invest Ophthalmol Vis Sci. 2010;51(2):744–751. DOI: 10.1167/iovs.09-3992.
53. Okamoto F., Okamoto Y., Hiraoka T. et al. Effect of vitrectomy for epiretinal membrane on visual function and vision-related quality of life. Am J Ophthalmol. 2009;147(5):869–874. DOI: 10.1016/j.ajo.2008.11.018.
54. Hiratsuka Y., Yamada M., Akune Y. et al. Assessment of vision-related quality of life among patients with cataracts and the outcomes of cataract surgery using a newly developed visual function questionnaire: the VFQ-J11. Jpn J Ophthalmol. 2014;58(5):415–422. DOI: 10.1007/s10384-014-0335-3.
55. Al Habash A., Nagshbandi A.A. Quality of Life After Combined Cataract and Minimally Invasive Glaucoma Surgery in Glaucoma Patients. Clin Ophthalmol. 2020;14:3049–3056. DOI: 10.2147/OPTH.S276124.
56. Samuelson T.W., Singh I.P., Williamson B.K. et al. Quality of Life in Primary Open-Angle Glaucoma and Cataract: An Analysis of VFQ-25 and OSDI from the iStent inject(R) Pivotal Trial. Am J Ophthalmol. 2021;229:220–229. DOI: 10.1016/j.ajo.2021.03.007.
57. Gothwal V.K., Seelam B., Mandal A.K. Quality of life following surgery for congenital glaucoma: findings of the LVPEI congenital glaucoma registry. Eye (Lond). 2019;33(4):659–667. DOI: 10.1038/s41433-018-0293-y.
58. Gothwal V.K., Bharani S., Mandal A.K. Quality of life of caregivers of children with congenital glaucoma: development and validation of a novel questionnaire (CarCGQoL). Invest Ophthalmol Vis Sci. 2015;56(2):770–777. DOI: 10.1167/iovs.14-15905.
2. Tham Y.C., Li X., Wong T.Y. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. DOI: 10.1016/j.ophtha.2014.05.013.
3. Neroev V.V., Zolotarev A.V., Karlova E.V. et al. Influence of treatment adherence on the progression of primary open-angle glaucoma in clinical setting. Vestn Ophtalmol. 2019;135(6):42–51 (in Russ.). DOI: 10.17116/oftalma201913506142.
4. Butt N.H., Ayub M.H., Ali M.H. Challenges in the management of glaucoma in developing countries. Taiwan J Ophthalmol. 2016;6(3):119–122. DOI: 10.1016/j.tjo.2016.01.004.
5. Agrawal P., Bradshaw S.E. Systematic Literature Review of Clinical and Economic Outcomes of Micro-Invasive Glaucoma Surgery (MIGS) in Primary Open-Angle Glaucoma. Ophthalmol Ther. 2018;7(1):49–73. DOI: 10.1007/s40123-018-0131-0.
6. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41(10):1403–1409. DOI: 10.1016/0277-9536(95)00112-k.
7. Mangione C.M., Lee P.P., Pitts J. et al. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol. 1998;116(11):1496–1504. DOI: 10.1001/archopht.116.11.1496.
8. Mangione C.M., Lee P.P., Gutierrez P.R. et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050–1058. DOI: 10.1001/archopht.119.7.1050.
9. McGwin G., Xie A., Mays A. et al. Visual field defects and the risk of motor vehicle collisions among patients with glaucoma. Invest Ophthalmol Vis Sci. 2005;46(12):4437–4441. DOI: 10.1167/iovs.05-0750.
10. Ivers R.Q., Norton R., Cumming R.G. et al. Visual impairment and risk of hip fracture. Am J Epidemiol. 2000;152(7):633–639. DOI: 10.1093/aje/152.7.633.
11. Enoch J., Jones L., Taylor D.J. et al. How do different lighting conditions affect the vision and quality of life of people with glaucoma? A systematic review. Eye (Lond). 2020;34(1):138–154. DOI: 10.1038/s41433-019-0679-5.
12. Ribeiro M.V., Hasten-Reiter Junior H.N., Ribeiro E.A. et al. Association between visual impairment and depression in the elderly: a systematic review. Arq Bras Oftalmol. 2015;78(3):197–201. DOI: 10.5935/0004-2749.20150051.
13. Mabuchi F., Yoshimura K., Kashiwagi K. et al. High prevalence of anxiety and depression in patients with primary open-angle glaucoma. J Glaucoma. 2008;17(7):552–557. DOI: 10.1097/IJG.0b013e31816299d4.
14. Jampel H.D., Frick K.D., Janz N.K. et al. Depression and mood indicators in newly diagnosed glaucoma patients. Am J Ophthalmol. 2007;144(2):238–244. DOI: 10.1016/j.ajo.2007.04.048.
15. Murphy S.L., Dubin J.A., Gill T.M. The development of fear of falling among community-living older women: predisposing factors and subsequent fall events. J Gerontol A Biol Sci Med Sci. 2003;58(10):M943–947. DOI: 10.1093/gerona/58.10.m943.
16. Janz N.K., Wren P.A., Guire K.E. et al. Fear of blindness in the Collaborative Initial Glaucoma Treatment Study: patterns and correlates over time. Ophthalmology. 2007;114(12):2213–2220. DOI: 10.1016/j.ophtha.2007.02.014.
17. Gabdrakhmanova A.F., Kurbanov S.A. Clinical and functional values of quality of life of primary open-angle glaucoma patients. National Journal glaucoma. 2015;14(4):29–35 (in Russ.).
18. Hollo G., Sandor N.G., Kothy P. et al. Influence of painless one-eye blindness on depression, anxiety and quality of life in glaucoma patients with a normal fellow eye. BMC Ophthalmol. 2021;21(1):89. DOI: 10.1186/s12886-021-01845-2.
19. Mabuchi F., Yoshimura K., Kashiwagi K. et al. Risk factors for anxiety and depression in patients with glaucoma. Br J Ophthalmol. 2012;96(6):821–825. DOI: 10.1136/bjophthalmol-2011-300910.
20. Agarkov N.M., Chukhraev A.M., Fabrikantov O.L., Yablokova N.V. Reduced quality of life in elderly patients with glaucoma. Ophthalmology in Russia. 2021;18(3):527–531 (in Russ.). DOI: 10.18008/1816-5095-2021-3-527-531.
21. Burr J.M., Kilonzo M., Vale L. et al. Developing a preference-based Glaucoma Utility Index using a discrete choice experiment. Optom Vis Sci. 2007;84(8):797–808. DOI: 10.1097/OPX.0b013e3181339f30.
22. Khachatryan N., Pistilli M., Maguire M.G. et al. A Review of Studies of the Association of Vision-Related Quality of Life with Measures of Visual Function and Structure in Patients with Glaucoma in the United States. Ophthalmic Epidemiol. 2021;28(3):265–276. DOI: 10.1080/09286586.2020.1863992.
23. Egorov E.A., Egorov A.E., Eliseeva T.O., Egorova T.E. Undesirable effects of hypotensive treatment of glaucoma. Literary review. RMJ Clinical Ophthalmology. 2011;12(3):111–113 (in Russ.).
24. Blane A. Through the Looking Glass: A Review of the Literature Investigating the Impact of Glaucoma on Crash Risk, Driving Performance, and Driver Self-Regulation in Older Drivers. J Glaucoma. 2016;25(1):113–121. DOI: 10.1097/IJG.0000000000000193.
25. Pelcic G., Ljubicic R., Barac J. et al. Glaucoma, depression and quality of life: multiple comorbidities, multiple assessments and multidisciplinary plan treatment. Psychiatr Danub. 2017;29(3):351–359. DOI: 10.24869/psyd.2017.351.
26. Mills T., Law S.K., Walt J. et al. Quality of life in glaucoma and three other chronic diseases: a systematic literature review. Drugs Aging. 2009;26(11):933–950. DOI: 10.2165/11316830-000000000-00000.
27. Nutheti R., Shamanna B.R., Nirmalan P.K. et al. Impact of impaired vision and eye disease on quality of life in Andhra Pradesh. Invest Ophthalmol Vis Sci. 2006;47(11):4742–4748. DOI: 10.1167/iovs.06-0020.
28. Kuroyedov A.V., Movsisyan A.B., Egorov E.A. et al. The profile of patients with primary open-angle glaucoma in the Russian Federation (preliminary results of a multicenter population-based study). Part 2. National Journal glaucoma. 2021;20(2):31–42 (in Russ.). DOI: 10.25700/2078-4104-2021-20-2-31-42.
29. Peters D., Heijl A., Brenner L. et al. Visual impairment and vision-related quality of life in the Early Manifest Glaucoma Trial after 20 years of follow-up. Acta Ophthalmol. 2015;93(8):745–752. DOI: 10.1111/aos.12839.
30. McKean-Cowdin R., Wang Y., Wu J. et al. Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology. 2008;115(6):941–948. DOI: 10.1016/j.ophtha.2007.08.037.
31. Van Gestel A., Webers C.A., Beckers H.J. et al. The relationship between visual field loss in glaucoma and health-related quality-of-life. Eye (Lond.). 2010;24(12):1759–1769. DOI: 10.1038/eye.2010.133.
32. Zhao C., Li J., Cun Q. et al. Impact of binocular integrated visual field defects on healthy related quality of life in glaucoma. Medicine (Baltimore). 2021;100(2):e24069. DOI: 10.1097/MD.0000000000024069.
33. Black A.A., Wood J.M., Lovie-Kitchin J.E. Inferior field loss increases rate of falls in older adults with glaucoma. Optom Vis Sci. 2011;88(11):1275–1282. DOI: 10.1097/OPX.0b013e31822f4d6a.
34. Noe G., Ferraro J., Lamoureux E. et al. Associations between glaucomatous visual field loss and participation in activities of daily living. Clin Exp Ophthalmol. 2003;31(6):482–486. DOI: 10.1046/j.1442-9071.2003.00712.x.
35. Jampel H.D. Glaucoma patients’ assessment of their visual function and quality of life. Trans Am Ophthalmol Soc. 2001;99:301–317. DOI: 10.1097/00061198-200204000-00012.
36. Purola P.K.M., Nättinen J.E., Parkkari M.M. et al. Improving health-related quality of life in glaucoma during 11 years and its association with vision loss and treatment of the disease. Acta Ophthalmol. 2022;100(1):e221–e232. DOI: 10.1111/aos.14883.
37. Kuroyedov A.V., Avdeev R.V., Alexandrov A.S. et al. Primary open-angle glaucoma: at what age and at what disease duration blindness can occur. Medical and biological problems of life. 2014;2(12):74–84 (in Russ.).
38. Heijl A., Leske M.C., Bengtsson B. et al. Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–1279. DOI: 10.1001/archopht.120.10.1268.
39. Lebedev O.I., Yavorsky A.E., Kalizhnikova E.A., Kovalevsky V.V. Benzalkonium chloride as one of the causes of insufficient efficacy in glaucoma surgeries. Oftalmokhirurgiya. 2012;2:48–50 (in Russ.).
40. Maeng K.J., Lee K., Kim S. et al. Effects of Glaucoma Medication on Dry Eye Syndrome and Quality of Life in Patients with Glaucoma. Korean J Ophthalmol. 2021;35(6):467–475. DOI: 10.3341/kjo.2021.0068.
41. Egorov E.A., Brezhnev A.Yu., Egorov A.E. Neuroprotection in glaucoma: modern possibilities and prospects. RMJ Clinical ophthalmology. 2014;2:108–112 (in Russ.).
42. Erichev V.P., Petrov S.Yu., Volzhanin A.V. et al. Alpha-adrenergic receptor agonists in terms of modern views on glaucoma monitoring and treatment. RMJ Clinical Ophthalmology. 2019;19(2):87–91 (in Russ.).
43. Ryabtseva A.A. Experience in neurometabolic treatment of primary open-angle glaucoma: approaches to the stabilization of visual functions. Medvestnik. (Electronic resource.) URL: https://medvestnik.ru/content/medarticles/Opyt-neirometabolicheskogo-lecheniya-pervichnoi-otkrytougolnoi-glaukomy-podhody-k-stabilizacii-zritelnyh-funkcii.html? (access date: 10.10.2021) (in Russ.).
44. Janz N.K., Wren P.A., Lichter P.R. et al. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology. 2001;108(11):1954–1965. DOI: 10.1016/s0161-6420(01)00874-0.
45. Guedes R.A., Guedes V.M., Freitas S.M. et al. Quality of life of medically versus surgically treated glaucoma patients. J Glaucoma. 2013;22(5):369–373. DOI: 10.1097/IJG.0b013e31824ceb8b.
46. Khanna C.L., Leske D.A., Holmes J.M. Factors Associated With Health-Related Quality of Life in Medically and Surgically Treated Patients With Glaucoma. JAMA Ophthalmol. 2018;136(4):348–355. DOI: 10.1001/jamaophthalmol.2018.0012.
47. Klink T., Sauer J., Korber N.J. et al. Quality of life following glaucoma surgery: canaloplasty versus trabeculectomy. Clin Ophthalmol. 2015;9:7–16. DOI: 10.2147/OPTH.S72357.
48. Pahlitzsch M., Klamann M.K., Pahlitzsch M.L. et al. Is there a change in the quality of life comparing the micro-invasive glaucoma surgery (MIGS) and the filtration technique trabeculectomy in glaucoma patients? Graefes Arch Clin Exp Ophthalmol. 2017;255(2):351–357. DOI: 10.1007/s00417-016-3550-4.
49. Kotecha A., Feuer W.J., Barton K. et al. Quality of Life in the Tube Versus Trabeculectomy Study. Am J Ophthalmol. 2017;176:228–235. DOI: 10.1016/j.ajo.2017.01.019.
50. McLeod L.D., Coon C.D., Martin S.A. et al. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharmacoecon Outcomes Res. 2011;11(2):163–169. DOI: 10.1586/erp.11.12.
51. Hirooka K., Nitta E., Ukegawa K. et al. Vision-related quality of life following glaucoma filtration surgery. BMC Ophthalmol. 2017;17(1):66. DOI: 10.1186/s12886-017-0466-7.
52. Okamoto F., Okamoto Y., Fukuda S. et al. Vision-related quality of life and visual function after vitrectomy for various vitreoretinal disorders. Invest Ophthalmol Vis Sci. 2010;51(2):744–751. DOI: 10.1167/iovs.09-3992.
53. Okamoto F., Okamoto Y., Hiraoka T. et al. Effect of vitrectomy for epiretinal membrane on visual function and vision-related quality of life. Am J Ophthalmol. 2009;147(5):869–874. DOI: 10.1016/j.ajo.2008.11.018.
54. Hiratsuka Y., Yamada M., Akune Y. et al. Assessment of vision-related quality of life among patients with cataracts and the outcomes of cataract surgery using a newly developed visual function questionnaire: the VFQ-J11. Jpn J Ophthalmol. 2014;58(5):415–422. DOI: 10.1007/s10384-014-0335-3.
55. Al Habash A., Nagshbandi A.A. Quality of Life After Combined Cataract and Minimally Invasive Glaucoma Surgery in Glaucoma Patients. Clin Ophthalmol. 2020;14:3049–3056. DOI: 10.2147/OPTH.S276124.
56. Samuelson T.W., Singh I.P., Williamson B.K. et al. Quality of Life in Primary Open-Angle Glaucoma and Cataract: An Analysis of VFQ-25 and OSDI from the iStent inject(R) Pivotal Trial. Am J Ophthalmol. 2021;229:220–229. DOI: 10.1016/j.ajo.2021.03.007.
57. Gothwal V.K., Seelam B., Mandal A.K. Quality of life following surgery for congenital glaucoma: findings of the LVPEI congenital glaucoma registry. Eye (Lond). 2019;33(4):659–667. DOI: 10.1038/s41433-018-0293-y.
58. Gothwal V.K., Bharani S., Mandal A.K. Quality of life of caregivers of children with congenital glaucoma: development and validation of a novel questionnaire (CarCGQoL). Invest Ophthalmol Vis Sci. 2015;56(2):770–777. DOI: 10.1167/iovs.14-15905.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
